# US 8,277,804 B2 · Antagonists of IL-6 to prevent or treat thrombosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,804 B2
- Document ID: US8277804B2
- Status: Granted
- Kind: B2
- Application number: 12/624,830
- Filed: 2009-11-24
- Published: 2010-06-10
- Granted: 2012-10-02
- Earliest claimed: 2008-11-25
- Assignees: Alderbio Holdings LLC
- Inventors: Jeffrey T. L. Smith
- Web page: https://patentgrep.com/patent/US8277804B2

## CPC

- C07K 16/248: {IL-6}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.

## Claims

### Claim 1

A method of reducing the risk of hypercoagulation or thrombosis in a subject having an elevated IL-6 level and an elevated D-dimer level by reducing the level of serum D-dimer in said subject, comprising administering to the subject an amount of an IL-6 antagonist, wherein said IL-6 antagonist is an antibody or antibody fragment that specifically binds human IL-6, wherein said antibody or antibody fragment comprises a variable light (VL) region containing the VL complementarity regions, CDR1, CDR2 and CDR3, respectively in SEQ ID NO:4, 5 and 6, and comprises a variable heavy (VH) region containing the VH complementarity regions, CDR1, CDR2 and CDR3, respectively in SEQ ID NO:7, 8 or 120 and 9, and which antibody or fragment is administered in an amount effective to reduce the level amount of serum D-dimer thereby reducing the risk of hypercoagulation or thrombosis in said subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the light chain comprises a polypeptide which is at least 90% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.

### Claim 3 (depends on 1)

The method of claim 1, wherein the heavy chain comprises a polypeptide which is at least 90% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.

### Claim 4 (depends on 1)

The method of claim 1, wherein the light chain comprises a polypeptide which is at least 95% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.

### Claim 5 (depends on 1)

The method of claim 1, wherein the heavy chain comprises polypeptide which is at least 95% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.

### Claim 6 (depends on 1)

The method of claim 1, wherein the light chain comprises polypeptide which is at least 98% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.

### Claim 7 (depends on 1)

The method of claim 1, wherein the heavy chain comprises a polypeptide which is at least 98% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.

### Claim 8 (depends on 1)

The method of claim 1, wherein the light chain comprises a polypeptide which is at least 99% identical to the light chain framework region having the sequence contained in SEQ ID NO:699.

### Claim 9 (depends on 1)

The method of claim 1, wherein the heavy chain comprises a polypeptide which is at least 99% identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.

### Claim 10 (depends on 1)

The method of claim 1, wherein the light chain comprises a polypeptide which is identical to the light chain framework region having the sequence contained in SEQ ID NO:699.

### Claim 11 (depends on 1)

The method of claim 1, wherein the heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence contained in SEQ ID NO:657.

### Claim 12 (depends on 1)

The method of claim 1, wherein the light chain comprises a polypeptide which is identical to the light chain framework region having the sequence contained in SEQ ID NO:2 or 20.

### Claim 13 (depends on 1)

The method of claim 1, wherein the heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence contained in SEQ ID NO:3, 18 or 19.

### Claim 14 (depends on 1)

The method of claim 1, wherein the light chain comprises a polypeptide which is identical to the light chain framework region having the sequence contained in SEQ ID NO: 20 and he heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence contained in SEQ ID NO: 18 or 19.

### Claim 15 (depends on 1)

The method of claim 1 wherein the antibody or fragment comprises human IgG1 constant regions.

### Claim 16 (depends on 14)

The method of claim 14 wherein the antibody or fragment comprises human IgG1 constant regions.

### Claim 17 (depends on 1)

The method of claim 1 wherein the D-dimer levels are determined before antibody administration.

### Claim 18 (depends on 1)

The method of claim 1 wherein said subject also has an elevated C-reactive protein (CRP) level prior to treatment.

### Claim 19 (depends on 1)

The method of claim 1 wherein said method further comprises the administration of at least one statin or anti-coagulant.

### Claim 20 (depends on 1)

The method of claim 1, wherein the anti-IL-6 antibody or antibody fragment is administered to the subject with a frequency at most once per period of approximately four weeks.

### Claim 21 (depends on 1)

The method of claim 1, wherein the subject's coagulation profile is assayed after treatment.

### Claim 22 (depends on 1)

The method of claim 1, wherein the subject's coagulation profile is assayed before treatment.

### Claim 23 (depends on 1)

The method of claim 1, wherein the anti-IL-6 antibody or antibody fragment has an elimination half-life of at least about 22 days.

### Claim 24 (depends on 1)

The method of claim 1, further comprising administration of one or more anti-coagulants or statins.

### Claim 25 (depends on 1)

The method of claim 1, wherein the subject's coagulation profile is assessed before or after treatment by measurement of the subject's serum level of one or more of D-dimer, Factor II, Factor V, Factor VIII, Factor IX, Factor XI, Factor XII, F/fibrin degradation products, thrombin-antithrombin III complex, fibrinogen, plasminogen, prothrombin, and von Willebrand factor.

### Claim 26 (depends on 1)

The method of claim 1, further comprising measuring the subject's international normalized ratio (INR) prior to administration of the anti-IL-6 antibody or antibody fragment and administering to the subject said anti-IL-6 antibody if the subject's INR is less than about 0.9.

### Claim 27 (depends on 1)

The method of claim 1, wherein the subject's serum D-dimer level is lowered to less than the upper limit of the normal reference range within 4 weeks of administering to the subject said anti-IL-6 antibody.

### Claim 28 (depends on 1)

The method of claim 1, wherein the subject treated has cancer.

### Claim 29 (depends on 1)

The method of claim 1, wherein the subject being treated is undergoing chemotherapy.

### Claim 30 (depends on 1)

The method of claim 1, further comprising measuring the level of IL-6 in the subject prior to treatment.

### Claim 31 (depends on 1)

The method of claim 1, further comprising measuring the level of C-reactive protein in the subject prior to treatment.

### Claim 32 (depends on 21)

The method of claim 21, wherein the subject's coagulation profile is assayed by a method comprising measuring the concentration of D-dimer in the subject's serum.

### Claim 33 (depends on 22)

The method of claim 22, wherein the subject's coagulation profile is assayed by a method comprising measuring the concentration of D-dimer in the subject's serum.

### Claim 34 (depends on 1)

The method of claim 1, wherein said antibody or fragment inhibits the interaction of IL-6 with gp130.

### Claim 35 (depends on 1)

The method of claim 1, wherein said antibody or fragment inhibits the interaction of IL-6 with IL-R 1.

### Claim 36 (depends on 1)

The method of claim 1, wherein said antibody or fragment inhibits the interaction of IL-6 with gp 130 and IL-6R1.

### Claim 37 (depends on 1)

The method of claim 1, wherein said antibody or fragment neutralizes IL-6 in vivo.

### Claim 38 (depends on 14)

The method of claim 14, wherein said antibody or fragment neutralizes IL-6 in vivo.

### Claim 39 (depends on 1)

The method of claim 1, wherein said antibody or fragment binds to IL-6 with a dissociation constant (KD) of less than or equal to 5×10−7, 10−7, 5×10−8, 10−8, 5×10−9, 10−9, 5×10−10, 10−10, 5×10−11, 10−11, 5×10−12, 10−12, 5×10−13, 10−13, 5×10−14, 10−14, 5×10−15 or 10−15.

### Claim 40 (depends on 1)

The method of claim 1, wherein said antibody or fragment binds to IL-6 with a dissociation constant of less than or equal to 5×10−10.

### Claim 41 (depends on 1)

The method of claim 1, wherein said antibody or fragment possesses a binding affinity (Kd) less than 50 picomolar.

### Claim 42 (depends on 1)

The method of claim 1, wherein said antibody or fragment possesses a Koff value less than or equal to 10−4 S−1.

### Claim 43 (depends on 1)

The method of claim 1, wherein said antibody or fragment is administered intravenously.

### Claim 44 (depends on 14)

The method of claim 14, wherein said antibody or fragment is administered intravenously.

### Claim 45 (depends on 1)

The method of claim 1, wherein said antibody or fragment is administered subcutaneously.

### Claim 46 (depends on 14)

The method of claim 14, wherein said antibody or fragment is administered subcutaneously.
